YU52800A - Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme - Google Patents

Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme

Info

Publication number
YU52800A
YU52800A YU52800A YUP52800A YU52800A YU 52800 A YU52800 A YU 52800A YU 52800 A YU52800 A YU 52800A YU P52800 A YUP52800 A YU P52800A YU 52800 A YU52800 A YU 52800A
Authority
YU
Yugoslavia
Prior art keywords
formula
making
heterocyclic ring
ring systems
salt
Prior art date
Application number
YU52800A
Other languages
English (en)
Inventor
Timothy Norris
Elizabeth Megan Hnatow
Francis John Lambert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU52800A publication Critical patent/YU52800A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Opisan je postupak dobijanja jedinjenja formule (1.3.0): koji se sastoji od pripremanja reakcione smese koja sadrzi u aprotonskom rastvaracu; u prisustvu jake baze u cvrstom obliku koja se bira iz grupe koju cine NaOH i KOH; i opciono, u prisustvu kataliticke kolicine cezijum-karbonata, Cs2CO3 ili katalizatora transfera faza, narocito kvaternerne amonijumove soli ili fosfonijumove soli, nakon cega sledi, zagrevanje pomenute reakcione smese u atmosferi azota; pri tome se dobije jedinjenje formule (1.3.0); a u pozeljnoj realizaciji aprotonski rastvarac je DMSO, jaka baza u cvrstom obliku je NaOH u obliku praha i peleta, a katalizator transfera faza je tetra-n-amonijumhlorid (TBAC), koji se koristi za dobijanje jedinjenja koje je korisno kao inhibitor 5-lipoksigenaze, formule a narocito, njegova sustinski cista metansulfonatna so.
YU52800A 1999-08-31 2000-08-24 Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme YU52800A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15161199P 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
YU52800A true YU52800A (sh) 2003-08-29

Family

ID=22539515

Family Applications (1)

Application Number Title Priority Date Filing Date
YU52800A YU52800A (sh) 1999-08-31 2000-08-24 Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme

Country Status (19)

Country Link
US (1) US6344563B1 (sh)
EP (1) EP1081146A1 (sh)
JP (1) JP2001106687A (sh)
KR (1) KR20010050224A (sh)
CN (1) CN1291609A (sh)
AR (1) AR022649A1 (sh)
AU (1) AU5360700A (sh)
BR (1) BR0003875A (sh)
CA (1) CA2317001A1 (sh)
CZ (1) CZ20003160A3 (sh)
HU (1) HUP0003438A3 (sh)
ID (1) ID29315A (sh)
IL (1) IL138088A0 (sh)
MX (1) MXPA00008505A (sh)
PL (1) PL342284A1 (sh)
RU (1) RU2177005C1 (sh)
TR (1) TR200002523A2 (sh)
YU (1) YU52800A (sh)
ZA (1) ZA200004436B (sh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5132861B2 (ja) 2000-03-24 2013-01-30 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬としてのアリール置換ピラゾール、トリアゾールおよびテトラゾール
EP3791880A1 (en) 2009-04-29 2021-03-17 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9406822A (pt) * 1993-06-14 1996-03-26 Pfizer Inibidores imidazol de lipoxigenase
SK281577B6 (sk) 1994-10-18 2001-05-10 Pfizer Inc. Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze
US6063928A (en) * 1994-10-18 2000-05-16 Pfizer Inc 5-lipoxygenase inhibitors
US5883106A (en) * 1994-10-18 1999-03-16 Pfizer Inc. 5-lipoxygenase inhibitors
PT863905E (pt) * 1995-09-18 2001-03-30 Pfizer Novos inibidores da lipoxigenase do imidazolo

Also Published As

Publication number Publication date
BR0003875A (pt) 2001-12-11
MXPA00008505A (es) 2005-07-25
AU5360700A (en) 2001-03-08
EP1081146A1 (en) 2001-03-07
CZ20003160A3 (cs) 2001-10-17
KR20010050224A (ko) 2001-06-15
PL342284A1 (en) 2001-03-12
HU0003438D0 (en) 2000-08-30
IL138088A0 (en) 2001-10-31
TR200002523A2 (tr) 2001-04-20
HUP0003438A3 (en) 2002-08-28
US6344563B1 (en) 2002-02-05
HUP0003438A2 (hu) 2001-08-28
CA2317001A1 (en) 2001-02-28
ID29315A (id) 2001-08-16
CN1291609A (zh) 2001-04-18
RU2177005C1 (ru) 2001-12-20
AR022649A1 (es) 2002-09-04
ZA200004436B (en) 2002-02-28
JP2001106687A (ja) 2001-04-17

Similar Documents

Publication Publication Date Title
MY138375A (en) Stable shaped particles of crystalline organic compounds
CA2331873A1 (en) Fumagillol derivatives and processes for preparing the same
YU100502A (sh) Novi $g (b) kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto
GB1490306A (en) 3-amino-indazolecarboxylic acid derivatives process for their preparation and their use as medicaments
WO2001040149A3 (en) Inhibition of polymerization of unsaturated monomers
PL273728A1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
CA2238163A1 (en) Triazinylaminostilbene compounds
MX9801205A (es) Compuestos de sales de aminoacidos y procesos para la produccion de los mismos.
ES8504653A1 (es) Un procedimiento para preparar nuevos derivados de eteno
CA2463625A1 (en) Method for producing 2-halogen-pyridine-carboxylic acid amides
YU52800A (sh) Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme
MY137475A (en) Chemical compounds.
CA2197467A1 (en) Method for the preparation of taxol and its derivatives
PL341281A1 (en) Novel acronicin compounds, method of obtaining them and pharmacological compoistions containing such compounds
JPS63203666A (ja) アゾールー半アミナール誘導体及びその硝酸化成禁止剤としての使用
GEP20033119B (en) Novel Octahydro-6, 10-Dioxo-6H-Pyridazino {1,2-a}{1 Carboxylic Acid Derivatives, Method for Preparation and Use Thereof
JPS57118555A (en) Leucotriene-analog compound, its preparation, and leucotriene-biosynthesis inhibiting agent containing said compound as active component
IL114676A0 (en) Methods for preparing multicarbide powders for hard materials
PT79724A (en) Chemical synthesis
CA2266357A1 (en) Pictet-spengler reaction for the synthesis of tetrahydroisoquinolines and related heterocyclic compounds
NO20004312L (no) Fremgangsmåte for fremstilling av 5-lipoksygenase-inhibitorer med forskjellige heterocycliske ringsystemer
HU9603178D0 (en) Process for producing benzyl-ethers with phase transformation
JPS57192342A (en) Isoprenylamine derivative
JPS5640622A (en) Procution of vinylidene halide
WO2002022569A8 (de) Verfahren zur herstellung chiraler verbindungen